NCT04640298已完成不适用
A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate Combined With Triamcinolone Hexacetonide (CINGAL®) to Provide Symptomatic Relief of Osteoarthritis of Hip Joint
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 25
- 试验地点
- 8
- 主要终点
- Numerical Rating Scale (NRS) Pain on Walking
研究概览
简要总结
This Trial will obtain clinical data to support an expanded indication for a single injection of Cingal used for the symptomatic relief of osteoarthritis in the hip joint.
详细描述
Single injection into the hip joint of a 4 ml unit dose of Cingal containing 88 mg (22 mg/ml) of cross-linked sodium hyaluronate and 18 mg (4.5 mg/ml) of triamcinolone hexacetonide (TH). Participants to be followed to 6 Months post-injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18 years or older
- •Body Mass Index (BMI) ≤ 35 kg/m2
- •Diagnosis of symptomatic osteoarthritic joint in the index hip (Kellgren-Lawrence grade I to III) to be treated with CINGAL injection.
- •Failed conservative treatment for joint osteoarthritis.
- •NRS on walking ≥4 and ≤ 9 in index hip.
- •Subject must be willing to abstain from other treatments of the index hip for the duration of the study.
- •Subject is willing to discontinue all analgesics including NSAIDs, except acetaminophen/paracetamol, at least seven days before the treatment injection and through the completion of the study.
- •Subject is willing to use only acetaminophen/paracetamol (up to a maximum of 4.0 grams per day per the package insert) for the treatment of joint pain for the duration of the study. At least forty-eight hours prior to the Baseline Visit and each follow-up assessment, the subject is willing to discontinue use of acetaminophen/paracetamol.
- •Subject is willing to maintain a stable dose of oral glucosamine and/or chondroitin sulfate products throughout the study, if taken prior to signing the informed consent form (ICF).
- •Able and willing to provide signed informed consent.
- •Baseline Inclusion Criteria
- •NRS pain on walking ≥4 and ≤ 9 in index hip
排除标准
- •History of hypersensitivity to any of the ingredients in the hyaluronan or corticosteroids
- •Infection or skin disease in the area of the injection site or hip joint
- •NRS pain on walking > 3 the contralateral hip.
- •NRS pain on walking > 3 in the ipsilateral knee or ankle joints.
- •Subject received an injection of Hyaluronic Acid (HA) and/or steroid in either joint within 6 months of signing the informed consent form (ICF). A subject will be excluded if they are planning to receive an HA or steroid injection (other than the study injection) in either joint during the course of this study.
- •Known inflammatory or autoimmune disorders (including rheumatoid arthritis, gout), or other pre-existing medical conditions that, in the opinion of the investigator, could impact treatment of the hip joint or affect the ability of the subject to accurately complete the study questionnaires and comply with the study requirements.
- •Subject is taking medications at the time of signing the ICF which could interfere with the treatment procedure, healing and/or assessments. This includes but is not limited to oral or injectable anticoagulant treatments, anti-aggregant platelet treatment, chronic opioid analgesics. Low dose aspirin used for cardiovascular protection is allowed if a stable regimen is maintained for the duration of the study.
- •Subjects who had an oral, intramuscular, intravenous, rectal suppository or topical (excluded in index hip only) corticosteroid within 30 days of signing the ICF are excluded. Topical corticosteroid use at any site other than the index hip is allowed.
- •Significant trauma to the index hip within 26 weeks of screening
- •Chronic use of narcotics or cannabis.
- •Ligament instability or tear in index hip.
- •Diagnosis of fibromyalgia
- •Diagnosis of osteonecrosis in index hip
- •Subject has significant varus or valgus deformity greater than 10 degrees in either knee.
- •Subject requires consistent use of an assistive device (e.g. wheelchair, walker, etc.) Occasional use of a cane is acceptable.
- •Uncontrolled diabetes with HbA1c of >7%.
- •Subject is a woman who is pregnant or breastfeeding at the Screening Visit or a woman of child bearing potential who refuses to use effective contraception during the course of the study.
- •Subject is receiving or in litigation for worker's compensation.
- •Otherwise determined by the investigator to be medically unsuitable for participation in this study.
- •Baseline Exclusion Criteria
- •Subject has a decrease of ≥ 2 in the NRS pain on walking from Screening to Baseline in the index hip.
- •Subject has a contraindication to continue with the study treatment injection based on the visual appearance of the synovial fluid aspirate.
研究组 & 干预措施
Cingal
Experimental
Single injection of Cingal into the hip joint of subjects diagnosed with osteoarthritis of the hip.
干预措施: Cingal (Device)
结局指标
主要结局
Numerical Rating Scale (NRS) Pain on Walking
时间窗: 6 months
Reduction of Index Hip Numerical Rating Scale (NRS) Pain on Walking from baseline to 6 months post injection was obtained from participant responses. The NRS Pain Score is an 11-point Likert scale ranged from 0 = No Pain to 10 = Worst Pain Level. A negative value for the change in NRS Pain Score indicates less pain post-treatment. A larger negative value indicates a higher level of improvement, and a better outcome.
次要结局
- Lequesne Hip Index(6 Months)
- Patient Global Assessment (PGA) Score(6 Months)
- The Outcomes Measures for Rheumatic Arthritis Clinical Trials-Osteoarthritis Research Society International (OMERACT-OARSI) Responder Index. A Calculated Percentage (%) of Participants Responding to Treatment(6 Months)
- Usage of Rescue Medication (Acetaminophen/Paracetamol). Number of Participants NOT Using Rescue Medication.(6 Months)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Study of Cingal® for Symptomatic Relief of Osteoarthritis of Ankle JointOsteoarthritis, AnkleNCT04640974Anika Therapeutics, Inc.25
已完成
不适用
Study of Cingal® for Symptomatic Relief of Osteoarthritis of Shoulder JointOsteoarthritis, ShoulderNCT04640961Anika Therapeutics, Inc.25
已完成
不适用
MONOVISC for Ankle Joint Pain Relief Due to OsteoarthritisOsteoarthritis AnkleNCT04204278Anika Therapeutics, Inc.25
进行中（未招募）
不适用
Combination of PRP and XLHA Prepared With RegenMatrix Medical Device To Treat Moderate to Severe Knee OsteoarthritisKnee OsteoarthritisNCT05727371RegenLab France SAS280
已完成
不适用
MONOVISC for Hip Joint Pain Relief Due to OsteoarthritisOsteoarthritis, HipNCT04204083Anika Therapeutics, Inc.25